Patients with cancer are often taking many medications, including chemotherapy, immune support, infection prophylaxis, plus medications for supportive care. Given the complexities of cancer treatment, finding the right medications for a patient can be difficult and often can cause debilitating side effects for the patient in the process. This is where pharmacogenomics can help.
Pharmacogenomics is the study of how genes affect a person’s response to medications. The OneOme RightMed comprehensive test uses pharmacogenomics to analyze a patient's DNA to determine which medications and dosages may work best, providing valuable information to guide chemotherapy and supportive care decisions.
Download our Guide to the RightMed test for oncology to learn more about how the RightMed comprehensive test may benefit oncology providers and patients.
The RightMed oncology report
The RightMed comprehensive test covers hundreds of medications across a broad range of conditions, including medications for oncology, psychiatric conditions, nausea, sleep, pain, and more. With the RightMed test, oncology providers can receive a specialty report that contains a subset of these medications used in oncology, including chemotherapies and supportive care medications.
The RightMed test: Helping oncology patients get the right treatment or dose
Oncology providers have been using somatic genetic testing on tumors for years. Now is the time to supplement that testing with germline pharmacogenomic testing using the OneOme RightMed comprehensive test.
The test results may help identify the right medications or right dose for your patients more quickly, both for chemotherapy and supportive care, potentially resulting in fewer adverse reactions, less trial and error, and more effective treatments for your patients.
HOW THE RIGHTMED TEST MAY HELP WITH PERSONALIZED CHEMOTHERAPY DOSING
The RightMed test covers several chemotherapies commonly used for breast cancer, colorectal cancer, lung cancer, blood cancers, and more. The RightMed test includes both first-line therapies as well as several targeted therapies, also known as the tyrosine kinase receptor inhibitors (TKIs). The RightMed test may help clinicians fine tune the dosing of these medications based on a patient’s genes.
For some chemotherapies, patients who are poor metabolizers (PM) can be at an increased risk for elevated exposure and severe chemotherapy-induced toxicity as a result of the accumulation of toxic compounds. Several first line therapies, such as Capecitabine1, Fluorouracil2, and Irinotecan3 can cause severe side effects such as liver toxicity, myelosuppression, arrhythmia, and death in patients who are poor metabolizers. In these cases the FDA label, CPIC, and other professional guidelines often recommend a simple dose reduction.
The RightMed test includes both pharmacokinetic genes (what the body does to the drug) and pharmacodynamic genes (what the drug does to the body). The genes on the RightMed test that have implications on chemotherapy medication response are pharmacokinetic and include several cytochrome P450 (CYP) genes, UDP glucuronosyltransferase family 1 member 1A (UGT1A1), dihydropyrimidine dehydrogenase (DPYD), nudix hydrolase 15 (NUDT15), and thiopurine S-methyltransferase (TPMT).
|
CHEMOTHERAPEUTIC AGENTS |
MEDICATIONS |
|
Alkylating Agents |
Ifosfamide |
|
Antimetabolites |
Capecitabine, Fluorouracil, Mercaptopurine, Methotrexate, Thioguanine |
Anti-microtubule Agents |
Cabazitaxel, Docetaxel, Ixabepilone, Paclitaxel, Vincristine, Vinorelbine |
|
Topoisomerase Inhibitors |
Etoposide, Teniposide, Irinotecan |
|
Antiandrogen Agents |
Enzalutamide |
|
Anti-estrogen Agent |
Exemestane, Tamoxifen |
|
Small Molecule Inhibitors |
Axitinib, Bortezomib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Everolimus, Gefitinib, Imatinib, Lapatinib, Nilotinib, Pazopanib, Ponatinib, Regorafenib, Ruxolitinib, Sorafenib, Sunitinib, Vemurafenib |
|
Other |
Belinostat, Trabectedin, Temsirolimus |
HOW THE RIGHTMED TEST MAY HELP WITH SUPPORTIVE CARE
The RightMed test includes many medications often prescribed in an oncology patient’s supportive care, including medications for pain, nausea, vomiting, sleep, hypertension, anxiety, depression, infection prophylaxis, and more.
By using the RightMed comprehensive test when prescribing medications for comorbidities, you may be able to find the right medication faster, reduce the number of adverse drug reactions, and make your patients more comfortable.
Gastrointestinal management (nausea/vomiting, appetite, gastritis, GERD)
Pain management
Neuropathy and non-opioid pain management
Mental health (antidepressants, anxiolytics)
Neuropsychiatry (sleep medicine, anticonvulsant, smoking cessation)
Antimicrobial (antifungal, antibiotic)
Anticoagulant and cardiovascular management
The benefits of the RightMed test
Pharmacogenomic tests, like the RightMed test, can benefit providers, health systems, and patients. They may help to:
reduce adverse
drug reactions
improve patient
adherence
improve
health and
economic cost
effectiveness
optimize dosing
change the
prescribing
paradigm from
reactive
to preventive
While many patients may benefit from the RightMed comprehensive test, there are specific medical events and conditions which may warrant a pharmacogenomic test for a particular patient more than others. Our Guide to the RightMed test for oncology includes a list of specific use cases.
RightMed patient story
“The RightMed test results, for me, mean that I don’t have to be anxious or scared going into a procedure.”
— Pam
Read Pam's full story >
Ready to get started?
If you are a patient, learn more about the RightMed test and how to get it by downloading our PATIENT TOOLKIT.
This test is not right for everyone. Consult your doctor to see if this test is right for you.
